Uveal melanoma modeling in mice and zebrafish.

Animal models Ocular melanoma Pharmacological intervention Uveal melanoma

Journal

Biochimica et biophysica acta. Reviews on cancer
ISSN: 1879-2561
Titre abrégé: Biochim Biophys Acta Rev Cancer
Pays: Netherlands
ID NLM: 9806362

Informations de publication

Date de publication:
15 Dec 2023
Historique:
received: 19 10 2023
revised: 08 12 2023
accepted: 11 12 2023
medline: 18 12 2023
pubmed: 18 12 2023
entrez: 17 12 2023
Statut: aheadofprint

Résumé

Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology have been extensively studied, there are significant gaps in our understanding of the early stages of UM tumor evolution and effective treatment to prevent metastatic disease remain elusive. A better understanding of the mechanisms that enable UM cells to thrive and successfully metastasize is crucial to improve treatment efficacy and survival rates. For more than forty years, animal models have been used to investigate the biology of UM. This has led to a number of essential mechanisms and pathways involved in UM aetiology. These models have also been used to evaluate the effectiveness of various drugs and treatment protocols. Here, we provide an overview of the molecular mechanisms and pharmacological studies using mouse and zebrafish UM models. Finally, we highlight promising therapeutics and discuss future considerations using UM models such as optimal inoculation sites, use of BAP1

Identifiants

pubmed: 38104908
pii: S0304-419X(23)00204-4
doi: 10.1016/j.bbcan.2023.189055
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

189055

Informations de copyright

Copyright © 2023. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Quincy C C van den Bosch (QCC)

Department of Ophthalmology, Rotterdam, the Netherlands; Clinical Genetics and Rotterdam, the Netherlands.

Annelies de Klein (A)

Clinical Genetics and Rotterdam, the Netherlands.

Rob M Verdijk (RM)

Pathology Erasmus MC Cancer Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.

Emine Killic (E)

Department of Ophthalmology, Rotterdam, the Netherlands.

Erwin Brosens (E)

Clinical Genetics and Rotterdam, the Netherlands. Electronic address: e.brosens@erasmusmc.nl.

Classifications MeSH